Local Institution

Amsterdam 1105 AZ

0 studies enrolling now · 44 studies all time

What they study most

Acute Coronary Syndrome, Acute Coronary Syndromes, Advanced Cancer, Advanced Gastric Cancer, Albuminuria, Breast Cancer, Cancer, Carcinoma, Non-small Cell Lung Cancer, Colitis, Ulcerative, Colorectal Cancer, Crohn's Disease, Deep-Vein Thrombosis

Studies at this site

• A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients — Completed
• A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy — Withdrawn before enrolling
• A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer — Completed
• An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread. — Completed
• An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3) — Completed
• Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) — Completed
• A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma — Completed
• A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037) — Completed
• An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread — Completed
• Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate — Completed
• Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139) — Completed
• An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma — Completed
• Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants — Withdrawn before enrolling
• A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based — Completed
• Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia — Completed
• A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart — Completed
• Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma — Completed
• Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive — Completed
• Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab — Completed
• PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma — Completed
• Multiple-Dose Study Apixaban in Pediatric Subjects With an Indwelling Central Venous Catheter — Stopped early
• Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC) — Completed
• Study of Immunotherapy to Treat Advanced Prostate Cancer — Completed
• Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis — Completed
• Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer — Completed
• Phase III Acute Coronary Syndrome — Stopped early
• Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives) — Completed
• Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 — Completed
• Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials) — Completed
• Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis — Completed
• Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial — Completed
• A Study of Abatacept in Patients With Active Ulcerative Colitis — Completed
• Pediatric Catheter-related Thrombosis Imaging Study — Completed
• A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas — Completed
• Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis — Stopped early
• Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C — Withdrawn before enrolling
• Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria — Completed
• BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies — Completed
• Remission and Joint Damage Progression in Early Rheumatoid Arthritis — Completed
• A Study of Abatacept in Patients With Active Crohn's Disease — Stopped early
• Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer) — Stopped early
• Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study — Completed
• A Phase I Study of BMS-275183 (Oral Taxane) Given on a Daily Schedule in Combination With Esomeprazole (Nexium) in Patients With Advanced Cancer — Stopped early
• Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung Cancer — Stopped early